Proteomic analysis of serum of women with elevated Ca-125 to differentiate malignant from benign ovarian tumors

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3265-3270

  Li, Li ^a   Xu, Yi ^a   Yu, Chun Xia ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

2D nano; CA 125; ITRAQ; LC ESI orbitrap MS MS; Ovarian cancer; Quantitative proteomics

Indexed keywords

EID: 84873594725     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3265     Document Type: Article

References (22)

1. Alzheimer's Association (2009). Cancer Facts and Figures 2009 US. Alzheimers Dement, 5, 234-70.
2. Amon LM, Law W, Fitzgibbon MP, et al (2010). Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS One, 5, e11137.
3. Awomoyi AA (2007). The human solute carrier family 11 member 1 protein (SLC11A1): linking infections, autoimmunity and cancer? FEMS Immunol Med Microbiol, 49, 324-9.
4. Bagan P, Berna P, Assouad J, et al (2008). Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur Respir J, 31, 140-2.
5. Bast RC Jr, Xu FJ, Yu YH, et al (1998). CA 125: the past and the future. Int J Biol Markers, 13, 179-87.
6. Beisiegel U, Utermann G (1979). An apolipoprotein homolog of rat apolipoprotein A-IV in human plasma. Isolation and partial characterisation. Eur J Biochem, 93, 601-8.
7. DeSouza L, Diehl G, Rodrigues MJ, et al (2005). Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res, 4, 377-86.
8. Dieplinger H, Ankerst DP, Burges A, et al (2009). Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev, 18, 1127-33.
9. Gao LL, Li FR, Jiao P, et al (2011). Apoptosis of human ovarian cancer cells induced by Paris chinensis dioscin via a Ca(2+)- mediated mitochondrion pathway. Asian Pac J Cancer Prev, 125, 1361-6.
10. Goswami T, Bhattacharjee A, Babal P, et al (2001). Natural-resistance-associated macrophage protein 1 is an H+/bivalent cation antiporter. Biochem J, 354, 511-9.
11. Huang da W, Sherman BT, Lempicki RA (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4, 44-57.
12. Keller A, Nesvizhskii AI, Kolker E, Aebersold R (2002). Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem, 74, 5383-92.
13. Lai CQ, Parnell LD, Ordovas JM (2005). The APOA1/C3/A4/ A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol, 16, 153-66.
14. Osman N, O'Leary N, Mulcahy E, et al (2008). Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J, 101, 245-7.
15. Pan S, Cheng L, White JT, et al (2009). Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. OMICS, 13, 345-54.
16. Qiu H, Zhu J, Yu J, Pu H, Dong R (2011). SLIT2 is epigenetically silenced in ovarian cancers and suppresses growth when activated. Asian Pac J Cancer Prev, 12, 791-5.
17. Sarandakou A, Protonotariou E, Rizos D (2007). Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci, 44, 151-78.
18. Schumacker PT (2006). Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell, 10, 175-6.
19. Searle S, Blackwell JM (1999). Evidence for a functional repeat polymorphism in the promoter of the human NRAMP1 gene that correlates with autoimmune versus infectious disease susceptibility. J Med Genet, 36, 295-9.
20. Searle S, Bright NA, Roach TI, et al (1998). Localisation of Nramp1 in macrophages: modulation with activation and infection. J Cell Sci, 111, 2855-66.
21. Whitehouse C, Solomon E (2003). Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol, 88, S152-7.
22. Wu WW, Wang G, Baek SJ, Shen RF (2006). Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res, 5, 651-8.